1. Evaluation of chimeric DNA vaccines consisting of premembrane and envelope genes of Japanese encephalitis and dengue viruses as a strategy for reducing induction of dengue virus infection-enhancing antibody response.
- Author
-
Sjatha F, Kuwahara M, Sudiro TM, Kameoka M, and Konishi E
- Subjects
- Animals, Antibodies, Neutralizing blood, Antibodies, Neutralizing immunology, Antibodies, Viral blood, Antibodies, Viral immunology, Antigens, Viral genetics, Antigens, Viral immunology, CHO Cells, Cell Line, Cricetulus, Dengue Vaccines genetics, Dengue Virus classification, Dengue Virus genetics, Encephalitis Viruses, Japanese classification, Encephalitis Viruses, Japanese genetics, Gene Expression, Humans, Immunization, Immunoglobulin G blood, Immunoglobulin G immunology, Male, Mice, Neutralization Tests, Recombinant Fusion Proteins chemistry, Recombinant Fusion Proteins genetics, Recombinant Fusion Proteins immunology, Serotyping, Vaccines, DNA genetics, Viral Envelope Proteins chemistry, Viral Envelope Proteins genetics, Viral Envelope Proteins immunology, Dengue immunology, Dengue Vaccines immunology, Dengue Virus immunology, Encephalitis Viruses, Japanese immunology, Vaccines, DNA immunology
- Abstract
Neutralizing antibodies induced by dengue virus (DENV) infection show viral infection-enhancing activities at sub-neutralizing doses. On the other hand, preimmunity against Japanese encephalitis virus (JEV), a congener of DENV, does not increase the severity of DENV infection. Several studies have demonstrated that neutralizing epitopes in the genus Flavivirus are mainly located in domain III (DIII) of the envelope (E) protein. In this study, chimeric premembrane and envelope (prM-E) gene-based expression plasmids of JEV and DENV1 with DIII substitution of each virus were constructed for use as DNA vaccines and their immunogenicity evaluated. Sera from C3H/He and ICR mice immunized with a chimeric gene containing DENV1 DIII on a JEV prM-E gene backbone showed high neutralizing antibody titers with less DENV infection-enhancing activity. Our results confirm the applicability of this approach as a new dengue vaccine development strategy., (© 2014 The Societies and Wiley Publishing Asia Pty Ltd.)
- Published
- 2014
- Full Text
- View/download PDF